阿替唑单抗
杜瓦卢马布
卡波扎尼布
医学
彭布罗利珠单抗
伦瓦提尼
索拉非尼
贝伐单抗
免疫疗法
无容量
肿瘤科
催眠药
肝细胞癌
内科学
重症监护医学
癌症
化疗
作者
Julien Edeline,Tim Meyer,Jean‐Frédéric Blanc,Jean‐Luc Raoul
出处
期刊:Cancers
[MDPI AG]
日期:2022-11-28
卷期号:14 (23): 5868-5868
被引量:4
标识
DOI:10.3390/cancers14235868
摘要
The standard of care of first-line systemic therapy for advanced hepatocellular carcinoma (HCC) is currently changing with the results of the IMbrave150 trial which are demonstrating superiority of the atezolizumab-bevacizumab combination over sorafenib, modifying this line of treatment for the first time in over 10 years. Recently, other immunotherapy-based combinations (durvalumab-tremelimumab, lenvatinib-pembrolizumab, cabozantinib-atezolizumab, and camrelizumab-rivoceranib) reported results in phase III studies, and might challenge this new standard of care. This revolution will lead to a considerable change in practice, and highlight challenges for future drug development. In this review, we will, firstly, describe results of the different combinations, and discuss the difficulties in selecting the first-line treatment. We will then present the different recommendations about second-line treatment following the first-line immunotherapy-based combination, discussing the rationale for the differences in existing recommendations. We will finally discuss the challenges for future drug development in advanced HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI